Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 10/20 | 0.58 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.45 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9662998 | 0.86 | CYP17A1 (0.58) | CYP17A1CYP11B1CYP11B2CYP19A1CYP26A1 | |
| SCHEMBL10697674 | 0.85 | CYP17A1 (0.52) | CYP17A1CYP11B1CYP11B2CYP19A1CYP26A1 | |
| SCHEMBL4054853 | 0.83 | CYP17A1 (0.68) | CYP17A1CYP11B1CYP11B2CYP19A1CYP26A1 | |
| SCHEMBL9190551 | 0.82 | CYP19A1 (0.50) | CYP17A1CYP11B1CYP11B2CYP19A1CYP26A1 | |
| SCHEMBL9663529 | 0.78 | CYP17A1 (0.61) | CYP17A1CYP19A1CYP3A4 | |
| SCHEMBL9190836 | 0.78 | CYP17A1 (0.57) | CYP17A1CYP11B1CYP11B2CYP19A1CYP26A1 | |
| SCHEMBL9663469 | 0.78 | CYP17A1 (0.59) | CYP17A1CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL9663438 | 0.75 | CYP17A1 (0.61) | CYP17A1CYP11B1CYP11B2CYP19A1CYP3A4 | |
| SCHEMBL9077571 | 0.75 | CYP19A1 (0.71) | CYP17A1CYP11B1CYP11B2CYP19A1CYP26A1 | |
| SCHEMBL19999188 | 0.74 | CYP19A1 (0.69) | CYP17A1CYP11B1CYP11B2CYP19A1CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1036003-C | A process for preparing (1H-azol-1-ylmethyl) substituted quinoxaline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1997-10-01 | — | — | CN | disclosed |
| CN-1033752-C | (1H-azol-1-ylmethyl) substituted quinoline or quinolinone derivatives | JANSSEN PHARMACEUTICA NV (SE) | 1997-01-08 | — | — | CN | disclosed |
| US-5500435-A | BENZIMIDAZOLES AND BENZOTRIAZOLES, TREATMENT OF RETINOID SENSITIVE SKIN DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1996-03-19 | — | — | US | disclosed |
| CN-1106005-A | A process for preparing (1H-azol-1-ylmethyl) substituted quinoxaline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-08-02 | — | — | CN | disclosed |
| CN-1106004-A | A process for preparing (1H-azol-1-ylmethyl) substituted quinazoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-08-02 | — | — | CN | disclosed |
| EP-0371564-B1 | (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-07-12 | — | — | EP | disclosed |
| US-5420147-A | Benzimidazoles, benzotriazoles, controlling metabolism of retinoids, skin cancer | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-05-30 | — | — | US | disclosed |
| EP-0371559-B1 | Use of benzimidazoles in the treatment of epithelial disorders | JANSSEN PHARMACEUTICA NV (BE) | 1994-10-12 | — | — | EP | disclosed |
| US-5342957-A | Suppress the metabolism of retinoids | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-08-30 | — | — | US | disclosed |
| CN-1020903-C | (1H-IMIDAZOL-1-YLMETHYL) SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THE PREPARATION THEREFOR | JANSSEN PHARMACEUTICA NV (BE) | 1993-05-26 | — | — | CN | disclosed |
| EP-0260744-B1 | (1H-IMIDAZOL-1-YLMETHYL) SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-12-16 | — | — | EP | disclosed |
| US-5157046-A | Systemic or topical application of substituted benzimidazole or benzotriazole which suppresses retinoid metabolism | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-10-20 | — | — | US | disclosed |
| US-5151421-A | Compounds for inhibition of metabolism of retinoids, for treatment for proliferation of epithelial cells and keratin disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-09-29 | — | — | US | disclosed |
| US-5028606-A | Retinoid metabolism inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-07-02 | — | — | US | disclosed |
| CN-1042912-A | (1H-oxazol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1990-06-13 | — | — | CN | disclosed |
| EP-0371559-A2 | Use of benzimidazoles in the treatment of epithelial disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-06-06 | — | — | EP | disclosed |
| US-4859684-A | (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use thereof in treating androgen dependent disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-08-22 | — | — | US | disclosed |
| CN-87106423-A | Novel (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and process for their preparation | — | 1988-04-20 | — | — | CN | disclosed |
| EP-0260744-A2 | (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-03-23 | — | — | EP | disclosed |